No benefit of hydroxychloroquine in patients affected by mild to moderate COVID-19 disease

The investigators found in a review article of 7 RCTs with a total of 4,984 COVID-19 patients, of which 1,721 (34.5%) received hydroxychloroquine or its congeners (HCQ group) while 3,091 (62.01%) received standard of care or had included antiviral medication (control group), that the present evidence shows no benefit of hydroxychloroquine in patients affected by mild to moderate COVID-19 disease.

Read more right here:
No benefit of hydroxychloroquine in patients affected by mild to moderate COVID-19 disease